Sandoz shares slipped following a conservative sales forecast, prompting fresh questions about pricing power and volume growth in the generic drug sector.

Novartis is accelerating internal artificial intelligence deployments, driving down reliance on third-party consultants and trimming commercial marketing expenditures.

GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.

Novartis boosted its full-year earnings guidance on resilient core portfolio momentum, even as late-stage clinical trial hurdles pressured bottom-line results.